Consequently, although further studies are needed to clarify the relationship between sTIL and other immune markers such as PD-L1, our findings support the potential benefit of combining immunotherapy with chemotherapy to improve treatment outcomes in patients with ER + HER2- breast cancer characterized by high sTIL levels. This evidence concerns the gene ESR1 and breast cancer.